SCA
BCRX icon

Spearhead Capital Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Spearhead Capital Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-45,953
Closed -$636K – 198
2021
Q4 		$636K Buy
45,953
+399
+0.9% +$5.28K 0.08% 82
2021
Q3 		$655K Sell
45,554
-132
-0.3% -$2.08K 0.09% 74
2021
Q2 		$722K Buy
45,686
+3,616
+9% +$49.1K 0.1% 74
2021
Q1 		$428K Buy
+42,070
New +$434K 0.06% 92

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Spearhead Capital Advisors's BCRX Position: Q1 2022 in Review

Spearhead Capital Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2022, closing a stake of 45,953 shares — an estimated $636K sold.

Spearhead Capital Advisors first reported a position in BCRX in Q1 2021 and held it in 4 quarters. The position peaked at $722K in Q2 2021. 233 funds tracked by Wall St. Rank hold BCRX as of Q1 2022.

  • Spearhead Capital Advisors reported no remaining BioCryst Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Spearhead Capital Advisors sold 45,953 BioCryst Pharmaceuticals shares in Q1 2022, an estimated $636K.
  • Spearhead Capital Advisors first reported a position in BioCryst Pharmaceuticals in Q1 2021 and held it in 4 quarters.
  • Spearhead Capital Advisors's BioCryst Pharmaceuticals position peaked at $722K in Q2 2021.
  • 233 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2022.

Based on Spearhead Capital Advisors's 13F filing for Q1 2022, filed 28 Apr 2022.